Inventor · disambiguated record
Andreas Evers
Also filed as: EVERS ANDREAS
32 granted patents·12 pending applications·109 citations·filing 2009–2024
96Inventor score
Top patents by PatentIndex Score
44 records- 0191US9181305B2Exendin-4 peptide analoguesSANOFI SA·Filed 2013·Granted Nov 10, 2015·19 cites·44 claims
- 0290US9745360B2Dual GLP1/GIP or trigonal GLP1/GIP/glucagon agonistsSANOFI SA·Filed 2013·Granted Aug 29, 2017·14 cites·36 claims
- 0389US10583174B2FGF21 compound / GLP-1R agonist combinations with optimized activity ratioSANOFI SA·Filed 2017·Granted Mar 10, 2020·6 cites·22 claims
- 0488US9750788B2Non-acylated exendin-4 peptide analoguesSANOFI SA·Filed 2014·Granted Sep 5, 2017·11 cites·23 claims
- 0587US9365632B2Exendin-4 derivatives as dual GLP1/glucagon agonistsSANOFI SA·Filed 2013·Granted Jun 14, 2016·9 cites·38 claims
- 0684US9758561B2Dual GLP-1/glucagon receptor agonists derived from exendin-4SANOFI SA·Filed 2015·Granted Sep 12, 2017·6 cites·34 claims
- 0782US9309207B2Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIaSANOFI SA·Filed 2015·Granted Apr 12, 2016·3 cites·17 claims
- 0881US9775904B2Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonistsSANOFI SA·Filed 2015·Granted Oct 3, 2017·4 cites·27 claims
- 0981US9771406B2Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4SANOFI SA·Filed 2015·Granted Sep 26, 2017·4 cites·31 claims
- 1080US9789165B2Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonistsSANOFI SA·Filed 2014·Granted Oct 17, 2017·4 cites·23 claims
- 1180US9751926B2Dual GLP-1/GIP receptor agonistsSANOFI SA·Filed 2014·Granted Sep 5, 2017·4 cites·27 claims
- 1280US8580777B2Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIaKALLUS CHRISTOPHER·Filed 2009·Granted Nov 12, 2013·4 cites·17 claims
- 1379US9694053B2Dual GLP-1/glucagon receptor agonistsSANOFI SA·Filed 2014·Granted Jul 4, 2017·4 cites·22 claims
- 1479US9126955B2Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIaSANOFI SA·Filed 2014·Granted Sep 8, 2015·3 cites·15 claims
- 1579US2024366727A1Fgf21 compound / glp-1r agonist combinations with optimized activity ratioSANOFI SA·Filed 2024·Application pending·0 cites
- 1677US10538567B2Compounds as peptidic trigonal GLP1/glucagon/GIP receptor agonistsSANOFI SA·Filed 2017·Granted Jan 21, 2020·2 cites·38 claims
- 1777US10519211B2Compounds as peptidic GLP1/glucagon/GIP receptor agonistsSANOFI SA·Filed 2017·Granted Dec 31, 2019·2 cites·30 claims
- 1877US8722655B2Macrocyclic urea and sulfamide derivatives as inhibitors of tafiaKALLUS CHRISTOPHER·Filed 2013·Granted May 13, 2014·3 cites·18 claims
- 1976US9982029B2Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonistsSANOFI SA·Filed 2016·Granted May 29, 2018·2 cites·34 claims
- 2076US9670261B2Functionalized exendin-4 derivativesSANOFI SA·Filed 2013·Granted Jun 6, 2017·2 cites·49 claims
- 2174US10792367B2Conjugates comprising an GLP-1/glucagon dual agonist, a linker and hyaluronic acidSANOFI SA·Filed 2017·Granted Oct 6, 2020·1 cites·36 claims
- 2271US2022401523A1Fgf21 compound / glp-1r agonist combinations with optimized activity ratioSANOFI SA·Filed 2022·Application pending·0 cites
- 2367US9221784B2Benzo[1,3]dioxine derivatives and their use as LPAR5 antagonistsSANOFI SA·Filed 2013·Granted Dec 29, 2015·1 cites·10 claims
- 2463US11046743B2Selective glucagon receptor agonists comprising a chelating moiety for imaging purposesANTAROS MEDICAL AB·Filed 2016·Granted Jun 29, 2021·1 cites·20 claims
- 2560US2020261542A1Fgf21 compound / glp-1r agonist combinations with optimized activity ratioSANOFI SA·Filed 2020·Application pending·0 cites
- 2659US2024360194A1New Peptides as Potent and Selective GIP Receptor AgonistsSANOFI SA·Filed 2022·Application pending·0 cites
- 2756US9688645B2Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIaSANOFI SA·Filed 2016·Granted Jun 27, 2017·0 cites·17 claims
- 2855US10758592B2Exendin-4 derivatives as dual GLP1/glucagon agonistsSANOFI SA·Filed 2017·Granted Sep 1, 2020·0 cites·23 claims
- 2954US10253079B2Functionalized Exendin-4 derivativesSANOFI SA·Filed 2017·Granted Apr 9, 2019·0 cites·30 claims
- 3052US11141489B2Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic acidSANOFI SA·Filed 2019·Granted Oct 12, 2021·0 cites·20 claims
- 3152US2025243255A1Crf2 receptor agonists and their use in therapySANOFI SA·Filed 2021·Application pending·0 cites
- 3251US8389764B2Urea and sulfamide derivatives as inhibitors of TAFIaKALLUS CHRISTOPHER·Filed 2009·Granted Mar 5, 2013·0 cites·7 claims
- 3351US2023103631A1Peptides as selective gip receptor agonistsSANOFI SA·Filed 2021·Application pending·0 cites
- 3450US2016220643A1Exendin-4 derivatives as dual glp1/glucagon agonistsSANOFI SA·Filed 2016·Application pending·0 cites
- 3550US2023127047A1Selective gip receptor agonists comprising a chelating moiety for imaging and therapy purposesANTAROS MEDICAL AB·Filed 2021·Application pending·0 cites
- 3649US2023250147A1Glp-1r agonistic peptides with reduced activitySANOFI SA·Filed 2020·Application pending·0 cites
- 3749US2023265152A1Glp-1r agonist / fgf21 fusion proteinsSANOFI SA·Filed 2020·Application pending·0 cites
- 3846US2015166625A1Exendin-4 Peptide AnaloguesSANOFI SA·Filed 2014·Application pending·0 cites
- 3946US2017022260A9Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonistsSANOFI SA·Filed 2014·Application pending·0 cites
- 4045US9834527B2Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticalsSANOFI SA·Filed 2014·Granted Dec 5, 2017·0 cites·9 claims
- 4143US9346757B2Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formationSANOFI SA·Filed 2013·Granted May 24, 2016·0 cites·9 claims
- 4243US9346762B2Pyrazole derivatives and their use as LPAR5 antagonistsSANOFI SA·Filed 2013·Granted May 24, 2016·0 cites·19 claims
- 4341US10806797B2Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugateSANOFI SA·Filed 2016·Granted Oct 20, 2020·0 cites·28 claims
- 4437US9932381B2Exendin-4 derivatives as selective glucagon receptor agonistsSANOFI SA·Filed 2015·Granted Apr 3, 2018·0 cites·21 claims
Join the waitlist — get patent alerts
Get an alert when Andreas Evers files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →